Bruno Lucidi has been named CEO of AgenTus Therapeutics, a subsidiary of Lexington, MA, cancer drug developer Agenus (NASDAQ: [[ticker:AGEN]]). AgenTus is also developing cancer treatments, but it will focus specifically on cell therapies. Lucidi’s industry experience includes senior roles at GlaxoSmithKline (NYSE: [[ticker:GSK]]), Johnson & Johnson (NYSE: [[ticker:JNJ]]), and Bristol-Myers Squibb (NYSE: [[ticker:BMY]]).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
